All-Cause Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Related Neoplasia in a Nationwide Cohort of 1154 Patients

Verheij, Eva P.; Munster, Sanne N. van; Nieuwenhuis, Esther; Cotton, Cary C.; Weusten, Blam; Herrero, Lorenza Alvarez; Alkhalaf, A.; Schenk, B.E.; Schoon, Erik J.; Curvers, Wouter L.; Koch, Arjun D.; Jonge, P.J.F. de; Tang, Thjon J.; Nagengast, WB; Westerhof, Jessie; Houben, Martin H.; Shaheen, Nicholas J.; Bergman, Jjghm; Pouw, Roos E.

doi:10.1055/s-0042-1744783

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, it may be a disproportionate amount of work with limited relevance, given that the PREFER study (NCT03222635), a prospective international multicenter study including all patients with high-risk EAC undergoing endoscopic therapy and surveillance, is currently running; in that study we also log patients undergoing surgery or no treatment. 3 However, because our research group is very much interested in individualizing treatment, Verheij et al 4 analyzed data in our Dutch nationwide cohort regarding EAC-unrelated death after successful endoscopic treatment in low-risk EAC. They found that the risk of dying of causes other than EAC after successful endoscopic therapy is 40 times higher than the risk of dying of recurrent EAC, and that the beneficial effect of intensive follow-up care is likely overstated.…”

Section: Responsementioning

confidence: 99%

Response

Nieuwenhuis

Pouw

2022

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Section: Responsementioning

confidence: 99%

Response

Nieuwenhuis

Pouw

2022

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Aktuelles vom europäischen Kongress zur gastrointestinalen Endoskopie

Kießlich¹

2023

Gastro-News

View full text Add to dashboard Cite

Endoscopic Management of Dysplastic Barrett’s Oesophagus and Early Oesophageal Adenocarcinoma

Eusebi,

Telese,

Castellana

et al. 2023

Cancers

View full text Add to dashboard Cite

Barrett’s oesophagus is a pathological condition whereby the normal oesophageal squamous mucosa is replaced by specialised, intestinal-type metaplasia, which is strongly linked to chronic gastro-oesophageal reflux. A correct endoscopic and histological diagnosis is pivotal in the management of Barrett’s oesophagus to identify patients who are at high risk of progression to neoplasia. The presence and grade of dysplasia and the characteristics of visible lesions within the mucosa of Barrett’s oesophagus are both important to guide the most appropriate endoscopic therapy. In this review, we provide an overview on the management of Barrett’s oesophagus, with a particular focus on recent advances in the diagnosis and recommendations for endoscopic therapy to reduce the risk of developing oesophageal adenocarcinoma.

show abstract

All-Cause Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Related Neoplasia in a Nationwide Cohort of 1154 Patients

Cited by 3 publications

References 0 publications

Response

Response

Aktuelles vom europäischen Kongress zur gastrointestinalen Endoskopie

Endoscopic Management of Dysplastic Barrett’s Oesophagus and Early Oesophageal Adenocarcinoma

Contact Info

Product

Resources

About